I bereby certify that this occrespondence is being filled was EFS-Web with the United States Patent and Trademark Office on July 25, 2006

PATENT
Attorney Docket No.: 082368-007400US
Client Reference No.: ONC-A0306P1-US

TOWNSEND and TOWNSEND and CREW LLP

v: /Aaron Hokamura/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No · 2042

Yusuke NAKAMURA et al.

Examiner:

Application No.: 10/573,522

Art Unit:

Filed: August 10, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

For: METHOD OF DIAGNOSING BREAST CANCER §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AD - AM provided herewith. Copies of references AD-AC are not provided in compliance with the provisions of 37 CFR [3,194(a)(2)]. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR $\S1.97(g)$ and (h), no inference should be made that the information and references cited are prior at merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Yusuke NAKAMURA et al. Application No.: 10/573,522 Page 2

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overnavment to the above-noted Denosit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 415-576-0200 Fax: 415-576-0300 KLB:341

Substitute for form 1448A/PTO				Complete if Known		
				Application Number	10/573,522	
INFORMATION DISCLOSURE				Filing Date	August 10, 2004	
STATEMENT BY APPLICANT			CANT	First Named Inventor	Nakamura, Yusuke	
				Art Unit		
	(Use as many sheets as n	ecessa	nd .	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	082368-007400US	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No 1	Document Number Number Kind Code ^{2 (Flores)}	Publication Date MM-DD-YYYY	Name of Patertise or Applicant of Cited Document	Pages Columns Lines Where Relevant Passages or Relevant Figures Appear
	AA	6,365,358 B1	04-02-2002	Hillman et al.	
	AB	2003/0157544 A1	08-21-2003	Gish et al.	
	AC	2003/0104418 A1	06-05-2003	Zhang et al.	

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Examiner Foreign Patent Document Publication Date Name of Patentee or Where Relevant Passages or Relevant Figures Appear Indials* MM-DD-YYYY Applicant of Cried Document Number⁴ Kind Code⁵ (if kno AD WO 02/04514 A2 01-17-2002 Conxa Corporation

Examiner Signature	Date Considered	

Substitute for form 1449B/PTO				Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/573,522	
				Filing Date	August 10, 2004	
				First Named Inventor	Nakamura, Yusuke	
				Art Unit		
(Use as many sheets as necessary)			1	Examiner Name		
Sheet	2	of	2	Altorney Docket Number	082368-007400US	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initals *	Cite No.1	include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tills of the item (book, magazine, journal, serial, symposium, calsiog, etc.), dete, pape(s), volume-issue number(s), publisher, city and/or country where published,	Т
	AE	ADAM, Paul J. et al.; "Arylamme N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro", <u>Molecular Cancer Research</u> 1:826-835 (September 2003)	С
	AF	DRESSMAN, Marlene A. et al.; "Gene expression in profiling detects gene amplification and differentiates tumor types in breast cancer"; <u>Cancer Research</u> 53:2194-2199 (May 1, 2003)	С
	AG	GEYLAN, Y.S. et al.; "Arylamine N-acetylfransferase activities in human breast cancer tissues"; Neoplasma 48(2):108-111 (2001)	С
	АН	LIPKOWITZ, Star; "Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer"; <u>Breast Cancer Research</u> 5(1):8-15 (2003)	C
	AJ	ORLOWSKI, Robert Z. and E. Claire Dees: "Applying drugs that affect the ubiquitin-protessome pathway to the therapy of breast cancer"; <u>Breast Cancer Res</u> 5:1-7 (2003)	C
	AJ	PEROU, Charles M. et al.; "Molecular protraits of human breast tumours"; Nature 406(6797):747-752 (August 2000)	C
	AK	SGROI, Dennis C. et al.; "In vivo gene expression profile analysis of human breast cancer progression"; <u>Cancer Research</u> 56:5656-5661 (November 15, 1999)	C
	AL	DATABASE; EBI Accession No. AAM56211; "Sequence 1 from patent US 6365356", June 20, 2002	С
	АМ	DATABASE; EBI Accession No. AX369194; "Sequence 1904 from patent WOQ204514", February 15, 2005	C
	Ì		Γ
	l		ı

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not n conformance and not considered include copy of this form with next communication to applicant.

Popicant unique citation designation manufact polisional, **Applicant* is no bities a check mark here if English language Translation is attached.